Replies to post #548 on Explosive Penny Stocks

[LiquidOTC]

CMXHY
PRIMA Study Shows Treatment with Privigen? Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

ROTTERDAM, Netherlands, June 27, 2012 /PRNewswire via COMTEX/ -- Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen? [Immune Globulin Intravenous (Human), 10% Liquid], an intravenous immunoglobulin (IVIg), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
PRIMA, a prospective, multicenter, open-label, single-arm study investigating the efficacy and safety of Privigen in previously IVIG-treated and untreated patients with CIDP achieved its primary efficacy endpoint, which was the percentage of patients responding--as measured by the Inflammatory Neuropathy Cause and Treatment (INCAT) scale--at study completion compared to baseline. The overall response rate was 60.7 percent. The 25-week treatment period permitted the observation that a response to IVIG can occur late (i.e., after more than 6 weeks of therapy). This finding may encourage some treating physicians to continue IVIG therapy longer in their CIDP patients before assessing whether or not the therapy is working.